Skip to content

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

A Single Arm, Prospective Clinical Trial Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00847730
Enrollment
33
Registered
2009-02-19
Start date
2009-02-28
Completion date
2009-09-30
Last updated
2024-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcers

Keywords

Ease of dressing application, dressing conformability and ease of dressing removal on diabetic foot ulcers using the ActiVAC therapy

Brief summary

The study is aimed at evaluating the clinician's perceived ease of using the V.A.C. GranuForm bride dressing and the patients perceived level of comfort during the dressing wear.

Detailed description

The objective of this study is to evaluate the ease of use of the V.A.C® GranuFoam™ Bridge dressing on Diabetic Foot Ulcers under ActiV.A.C® negative pressure wound therapy for a period of 48-72 hrs (+6hrs). Ease of use will be determined based on the feedback on the following characteristics 1) Ease of dressing application 2) Ease of dressing removal and 3) Ease of dressing conformability. Additionally patient feedback on comfort during wear will also be collected. Patients currently prescribed to V.A.C.® Therapy will be enrolled in the trial.

Interventions

DEVICEV.A.C. Negative Pressure Wound Therapy System

This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds

Sponsors

KCI USA, Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or Female subjects must be ≥ 18 years of age 2. Subject is willing and able to provide written informed consent and comply with protocol required procedures 3. Subject has a calcaneal, dorsal or plantar diabetic foot ulcer no greater than a Grade 2 on the Wagner Grading System for which ActiV.A.C.® Therapy has been prescribed and requires off loading of the SensaT.R.A.C. PadTM 4. Subject has a foot ulcer that is ≥ 1.5cm2 but no greater than 84 cm2 5. Female subject that is willing to use an effective method of contraception for the duration of the study, is permanently sterilized, or post-menopausal as defined by cessation of menses for at least twelve (12) months prior to enrollment. Acceptable means of contraception is defined as use of Birth control pills, Depo Provera® , Norplant® , IUD (intrauterine device), Diaphragm with spermicide, Condom with spermicide

Exclusion criteria

1. Subject's wound measures \> 84 cm2 2. Presence of untreated cellulitis 3. Presence of untreated or refractory osteomyelitis (including untreated necrotic bone, non-viable tissue and infected bone) 4. History of radiation to the wound area 5. History of thermal injury in the wound area 6. Known hypersensitivity to any disposable component of the V.A.C.® Therapy system 7. Necrotic tissue with eschar present that cannot be debrided prior to subject enrollment in the study 8. Subject is exhibiting active signs and symptoms of infection of the wound(i.e. increased redness or erythema, increased pain, warmth, purulent drainage) 9. Past or current enrollment in this clinical study or any other clinical study within 30 days 10. Female Subject who is pregnant or is unwilling to use acceptable means of contraception during the duration of her participation in the study 11. Subject exhibits significant peri-wound issues that in the opinion of the investigator can interfere with the study assessments 12. Subject is unable to co-operate with study assessments or has a history of non-compliance with off-loading modalities or has a foot deformity that in the opinion of the investigator does not allow for appropriate dressing application or off loading placement.

Design outcomes

Primary

MeasureTime frameDescription
Ease of Use Assessment48-72 hours (+6 hours) time periodEach subject was assessed on the three scales (each scale was 1-Poor, 2 - Fair, 3 - Good, 4 - Excellent) and given a score on each individual characteristic (Ease of Dressing Application, Ease of Conformability, and Ease of Dressing Removal). The scores were then summed for each subject with possible range being 3-12. If the subject had a total score greater than or equal to 6, and a minimum score of greater than or equal to 2 on each individual characteristic then the subject was included in the percentage of subjects with satisfactory performance. Note that for each scale higher scores indicate better outcomes.

Countries

United States

Participant flow

Participants by arm

ArmCount
V.A.C Bridge Dressing
This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
33
Total33

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyMultiple interruptions in therapy8

Baseline characteristics

CharacteristicV.A.C Bridge Dressing
Age, Continuous57.2 years
STANDARD_DEVIATION 13.32
Race/Ethnicity, Customized
American Indian or Alaskan Native
1 Participants
Race/Ethnicity, Customized
Black or African American
1 Participants
Race/Ethnicity, Customized
Hispanic or Latino
12 Participants
Race/Ethnicity, Customized
White
19 Participants
Region of Enrollment
United States
33 participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
24 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 33
other
Total, other adverse events
8 / 33
serious
Total, serious adverse events
0 / 33

Outcome results

Primary

Ease of Use Assessment

Each subject was assessed on the three scales (each scale was 1-Poor, 2 - Fair, 3 - Good, 4 - Excellent) and given a score on each individual characteristic (Ease of Dressing Application, Ease of Conformability, and Ease of Dressing Removal). The scores were then summed for each subject with possible range being 3-12. If the subject had a total score greater than or equal to 6, and a minimum score of greater than or equal to 2 on each individual characteristic then the subject was included in the percentage of subjects with satisfactory performance. Note that for each scale higher scores indicate better outcomes.

Time frame: 48-72 hours (+6 hours) time period

Population: ITT (Intent to Treat) population.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Application2-Fair3 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Comfortability4-Excellent20 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Removal2-Fair1 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Application1-Poor0 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Application3-Good14 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Application4-Excellent13 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Comfortability1-Poor0 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Comfortability2-Fair1 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Comfortability3-Good9 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Removal1-Poor0 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Removal3-Good4 Participants
VAC GranuFoam Bridge DressingEase of Use AssessmentEase of Dressing Removal4-Excellent25 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026